PT1556489E - Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade - Google Patents
Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade Download PDFInfo
- Publication number
- PT1556489E PT1556489E PT03767876T PT03767876T PT1556489E PT 1556489 E PT1556489 E PT 1556489E PT 03767876 T PT03767876 T PT 03767876T PT 03767876 T PT03767876 T PT 03767876T PT 1556489 E PT1556489 E PT 1556489E
- Authority
- PT
- Portugal
- Prior art keywords
- treating
- pharmaceutical composition
- obesity
- medicine
- preparing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0213725A FR2846559B1 (fr) | 2002-10-31 | 2002-10-31 | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1556489E true PT1556489E (pt) | 2011-05-31 |
Family
ID=32104388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT03767876T PT1556489E (pt) | 2002-10-31 | 2003-10-31 | Composi??o farmac?utica para a prepara??o de um medicamento destinado a tratar e/ou a prevenir uma patologia ligada a uma conduta obsessiva ou a obesidade |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8859537B2 (pt) |
| EP (1) | EP1556489B1 (pt) |
| JP (1) | JP4852245B2 (pt) |
| AT (1) | ATE497003T1 (pt) |
| AU (1) | AU2003292310A1 (pt) |
| CA (1) | CA2503546C (pt) |
| DE (1) | DE60335892D1 (pt) |
| DK (1) | DK1556489T3 (pt) |
| ES (1) | ES2362092T3 (pt) |
| FR (1) | FR2846559B1 (pt) |
| PT (1) | PT1556489E (pt) |
| WO (1) | WO2004042063A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2846559B1 (fr) * | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US20060204599A1 (en) * | 2005-03-14 | 2006-09-14 | Wheat Jared R | Dietary supplement and method of using same |
| MX353096B (es) | 2010-08-19 | 2017-12-19 | Buck Institute For Age Res Star | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| JP7683882B2 (ja) * | 2019-04-09 | 2025-05-27 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ストレスに対するセロトニン４受容体アゴニストの予防的有効性 |
| CN115581201A (zh) * | 2022-08-26 | 2023-01-10 | 云南省农业科学院花卉研究所 | 以茎段为外植体诱导的二倍体月季f1-61的植株再生方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ258320A (en) * | 1992-11-03 | 1996-12-20 | Synaptic Pharma Corp | Dna encoding a human receptor 5-ht4b receptor and diagnostic use |
| US5472866A (en) * | 1992-12-24 | 1995-12-05 | Synaptic Pharmaceutical Corporation | DNA encoding 5-HT4A serotonin receptors |
| JP2000516198A (ja) * | 1996-02-15 | 2000-12-05 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | セロトニンの再取り込み阻害剤の胃腸に対する作用を克服するための５ｈｔ４レセプター拮抗剤の使用 |
| WO2000064441A2 (en) * | 1999-04-28 | 2000-11-02 | Respiratorius Ab | Compound for use as a medicament for treatment of disorders involving bronchocontraction |
| GB9913850D0 (en) * | 1999-06-14 | 1999-08-11 | Janssen Pharmaceutica Nv | Cloning and expression of a novel receptor |
| FR2811989A1 (fr) * | 2000-07-18 | 2002-01-25 | Sanofi Synthelabo | Derives de polyfluoroalkytriazole, leur preparation et leur application en therapeutique |
| FR2846559B1 (fr) * | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
-
2002
- 2002-10-31 FR FR0213725A patent/FR2846559B1/fr not_active Expired - Fee Related
-
2003
- 2003-10-31 JP JP2004549279A patent/JP4852245B2/ja not_active Expired - Fee Related
- 2003-10-31 DK DK03767876.0T patent/DK1556489T3/da active
- 2003-10-31 DE DE60335892T patent/DE60335892D1/de not_active Expired - Lifetime
- 2003-10-31 ES ES03767876T patent/ES2362092T3/es not_active Expired - Lifetime
- 2003-10-31 CA CA2503546A patent/CA2503546C/fr not_active Expired - Lifetime
- 2003-10-31 AT AT03767876T patent/ATE497003T1/de active
- 2003-10-31 PT PT03767876T patent/PT1556489E/pt unknown
- 2003-10-31 EP EP03767876A patent/EP1556489B1/fr not_active Expired - Lifetime
- 2003-10-31 WO PCT/FR2003/003262 patent/WO2004042063A1/fr not_active Ceased
- 2003-10-31 AU AU2003292310A patent/AU2003292310A1/en not_active Abandoned
-
2005
- 2005-04-29 US US11/118,745 patent/US8859537B2/en not_active Expired - Lifetime
-
2008
- 2008-10-23 US US12/256,642 patent/US8436021B2/en not_active Expired - Fee Related
-
2013
- 2013-04-03 US US13/855,806 patent/US9168250B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4852245B2 (ja) | 2012-01-11 |
| US8436021B2 (en) | 2013-05-07 |
| JP2006520319A (ja) | 2006-09-07 |
| CA2503546A1 (fr) | 2004-05-21 |
| FR2846559B1 (fr) | 2007-06-15 |
| DE60335892D1 (de) | 2011-03-10 |
| WO2004042063A1 (fr) | 2004-05-21 |
| ES2362092T3 (es) | 2011-06-28 |
| US20130274293A1 (en) | 2013-10-17 |
| US8859537B2 (en) | 2014-10-14 |
| AU2003292310A1 (en) | 2004-06-07 |
| US9168250B2 (en) | 2015-10-27 |
| CA2503546C (fr) | 2014-02-11 |
| WO2004042063A8 (fr) | 2005-08-11 |
| EP1556489A1 (fr) | 2005-07-27 |
| FR2846559A1 (fr) | 2004-05-07 |
| US20060116341A1 (en) | 2006-06-01 |
| EP1556489B1 (fr) | 2011-01-26 |
| DK1556489T3 (da) | 2011-05-16 |
| ATE497003T1 (de) | 2011-02-15 |
| US20090124592A1 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511139A (pt) | compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente | |
| MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
| BR0111898A (pt) | Métodos de tratamento de doenças de proliferação celular, e de um distúrbio associado com a atividade de cinesina ksp, método de inibição da cinesina ksp, composto, método de triagem de moduladores da cinesina kps, e, método de triagem de compostos que se ligam à cinesina ksp | |
| MXPA05006569A (es) | Compuestos que inhiben la proteina cinasa-2 activada por la proteina cinasa activada por el mitogeno. | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| PH12015501744B1 (en) | Therapeutic and diagnostic target for cancer comprising dll3 binding reagents | |
| BR0306988A (pt) | Piridazinonas substituìdas como inibidores de p38 | |
| NO20045429L (no) | Kombinasjon av organiske forbindelser | |
| WO2001062341A3 (en) | Combination product for the treatment of obesity | |
| NO20045354L (no) | Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser | |
| MX2007006204A (es) | Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa. | |
| DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
| BRPI0409523A (pt) | método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica | |
| SG155046A1 (en) | Process for modifying drug crystal formation | |
| DK1143955T3 (da) | En kombination af FBPase-inhibitorer og insulinsensibiliseringsmidler til behandling af diabetes | |
| NO20051304L (no) | Agonisme av 5HT2a reseptoren for behandling av termoregulatorisk dysfunksjon | |
| DK1456380T3 (da) | SMAD7-inhibitorer til behandling af CNS-sygdomme | |
| SG165387A1 (en) | 5-lipoxygenase-activating protein (flap) inhibitors | |
| WO2004084943A8 (en) | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation | |
| AU2003292310A1 (en) | Pharmaceutical composition for preparing a medicine for treating and/or preventing a pathology related to an obsessive behaviour or obesity | |
| EA200702212A1 (ru) | Способ лечения или профилактики разрушения кости или остеопороза | |
| BR0315247A (pt) | Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit | |
| EA200501865A1 (ru) | Аналоги тиовольфраматов и их применение | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| BRPI0408984A (pt) | método para tratar uma condição de doença mediada por células neutrofìlicas em um paciente, e, uso de um composto de ligação de histamina |